US regulators add rare vision-loss warning to popular diabetes and weight-loss medications

Popular weight-loss and diabetes medications such as Ozempic and Wegovy will now carry a new warning about a rare eye condition that can sometimes lead to permanent vision loss. The U.S. Food and Drug Administration announced that the risk will be added to the labelling of all GLP-1 drugs, a class of blockbuster medications that includes about a dozen injectable or pill-based brands like Zepbound and Mounjaro.

The Condition And Data

The eye condition is called non-arteritic anterior ischemic optic neuropathy and causes major vision loss due to decreased blood flow to the optic nerve. An FDA analysis of more than 125 clinical trials showed that the problem happened in about 6 of every 100,000 patients who took a GLP-1 drug for at least one year. For people taking a placebo or other glucose-lowering drugs, the rate was less than 4 per 100,000. FDA scientists started looking into the issue after a 2024 medical paper linked the condition to patients taking semaglutide, the active drug in Ozempic.

Symptoms And Advice

Symptoms of the condition include blurred vision, blind spots, and distorted colors. The FDA advises patients who experience any of these visual disturbances to contact a doctor immediately. While the problem has been reported across all GLP-1 drugs, regulators note that the exact underlying cause is still not understood.

Context

Drug regulators frequently update product labels as new medical research and large-scale data analyses reveal rare side effects that may not appear during initial clinical testing. GLP-1 receptor agonists have seen massive global demand in recent years for treating type 2 diabetes and helping with chronic weight management. Patients using prescription medications are encouraged to stay in close contact with their healthcare providers regarding any unexpected bodily changes.